17 publications
Name | Date | Type | Actions |
---|---|---|---|
2012 sales up 5.0% Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%. |
24/01/2013 | Public releases | |
2012, return to growth Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements. |
26/03/2013 | Public releases | |
Q1 2013 sales Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
16/04/2013 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version) The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013. |
16/04/2013 | Public releases | |
Q2 2013 sales Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like. |
16/07/2013 | Public releases | |
The reference products demonstrate solid growth Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013. |
29/08/2013 | Public releases | |
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
24/10/2013 | Public releases | |
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
16/12/2013 | Public releases | |
2017 sales: €352.2 million 7.6% like-for-like growth in essentials products The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%. |
23/01/2018 | Public releases | |
Strong growth in all key financial indicators in 2017 ebit up 9.4% to €46.0 million net income - group share up 25.2% to €34.8 million At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements. |
15/03/2018 | Public releases |